Reducing pyrophosphate deposition with calcium antagonists

• US 6,221,861 B1
• Filed: 07/09/1999
• Issued: 04/24/2001
• Est. Priority Date: 07/10/1998
• Status: Expired due to Fees

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: Seegmiller, J. Edwin
• Primary Examiner(s): KRASS, FREDERICK F
• Application Number:
  US09/350,694
• Time in Patent Office: 655 Days
• Field of Search: 514/220, 514/523, 514/357, 514/255.01, 514/825
• US Class Current: 514/220
• CPC Class Codes: A61K 31/275 Nitriles; Isonitriles
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: A61K 31/495 having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazinesA61K31/48 takes precedence ; with three nitrogen atoms A61K31/53
• CPC Class Codes: A61K 31/55 having seven-membered rings, e.g. azelastine, pentylenetetrazole
• CPC Class Codes: A61P 3/14 for calcium homeostasis vitamin D A61P3/02; parathyroid hormones A61P5/18; calcitonin A61P5/22; osteoporosis A61P19/10; bone metastasis A61P35/04
• CPC Class Codes: Y10S 436/815 Test for named compound or class of compounds
• CPC Class Codes: Y10T 436/166666 of inorganic phosphorus compound in body fluid

Abstract

This invention provides a method of treating an animal with pyrophosphate gout or osteoarthritis comprising administering an effective amount of a calcium antagonist, thereby reducing calcium pyrophosphate crystal deposition in the animal.

Claims

1. A method for reducing calcium pyrophosphate crystal deposition so as to treat an animal with pyrophosphate gout comprising administering an effective amount of a calcium antagonist to said animal, thereby reducing calcium pyrophosphate crystal deposition in the animal.

2. The method of claim 1, wherein the animal is a mammal.

3. The method of claim 2, wherein the mammal is a human.

4. The method of claim 1, wherein the calcium antagonist is diltiazem.

5. The method of claim 1, wherein the calcium antagonist is nifedipine.

6. A method for reducing calcium pyrophosphate crystal deposition in an animal in need thereof comprising administering an effective amount of a calcium antagonist to said animal, thereby reducing calcium pyrophosphate crystal deposition in the animal.

7. The method of claim 6, wherein the animal is a mammal.

8. The method of claim 7, wherein the mammal is a human.

9. The method of claim 6, wherein the calcium antagonist is diltiazem.

10. The method of claim 6, wherein the calcium antagonist is nifedipine.